New daily instances of COVID-19 and deaths from the disease have shown a downward trend since August 13, the Ministry of Health said on August 18, but warned against laxity, highlighting that a five-day period consisting of a very short period in the context of A Pandemic At a press conference , the secretary of the Union’s Ministry of Health, Rajesh Bhushan, said that despite a sustained point of lakh 7-8 coronavirus tests consistent with the day, the positivity rate has been higher than 10.03% in the first week.July to 7.72% in the last seven days.
When asked to comment on media reports on a more fatal strain of coronavirus discovered in Malaysia and whether there is an Indian link to this mutation, NITI member Aayog, Dr. VK Paul, said: “We have also noticed the reports.At the moment, we haven’t done it”.anything to convey, however, we have taken note of it.”
Some media reports have claimed that a new, deadliest mutation of the virus was discovered in Malaysia in a forty-five-case organization that began on a user returning from India.
Bhushan, in his comments, said: “The new instances of August 13 have risen from more than 64,000 to 55,079 now.There’s a downward trend. But five days is very short in the context of a pandemic and there is no room for laxity.”precautionary measures, containment, testing and surveillance.”
He added: “Absolute deaths (per day) also decreased from 1,007 on August 13 to August 876 on August 17.These two parameters give us some satisfaction, but there is no explanation as to why we let our guard pass.”
Paul said the slow rise in recovery rates and the minimisation of the mortality rate are “reassuring” and are “positive signs” that the COVID-19 pandemic is under control.
Follow our LIVE blog for updates on the new coronavirus pandemic
“In addition, the number of COVID-1nine tests consistent with the day is greater than nine lakh consistent with the day, which is remarkable.Testing is the key to containing the disease and reducing mortality and outcomes,” he said.
Declaring that he has realized that some others are relaxing about maintaining the norms of social estating, hand hygiene and dressing in masks, Paul warned that this can result in the loss of achievements that have been achieved so far.
On the decline of new instances over the more than five days, Paul said that while the weekly COVID-19 stage update is reassuring, the challenge is not yet over.
Read also the Oxford-AstraZeneca vaccine may be the first vaccine available for Indians
“There is a giant vulnerable population in the country, so the virus still has a chance of harming us,” he said.
On the vaccine front, Paul, who chairs the national organization specializing in the management of vaccines that oppose COVID-19, referred to the Prime Minister’s speech on Independence Day that 3 vaccines are being developed in India and are in the stages of human trials.
“One of them will be testing in Phase 3 or tomorrow.The other two are in Phase 1 and 2.We’ve looked at candidate vaccines and there’s smart progress,” he said.
A review of the vaccine’s chain of origin and how it would be obtained is ready, Paul said.
As needed, detailed development plans will be adopted and micro level for the delivery of vaccines in a clinical technique on vaccine characteristics, he said.
In reporting on Monday’s committee meeting, Paul said they had been in talks with vaccine brands to find out what services they expected from the government.
In reaction to a media question, he also said: “We asked vaccine brands to understand what the values imaginable might be.Pricing is very complex because some of these vaccines are at an early stage.We have a review of what the diversity of value might be., however, are data that will be subtle as we move forward.”
Read also How the smell of COVID-19, the loss differs from the decoded cold
Individual vaccine brands were asked to provide clearer knowledge of their individual production functions, how their functions would evolve over time, and actively inspire them to perform their functions with facilities, he said.
“India has enormous capacity in vaccine manufacturing,” Paul said.
He said the progression of a vaccine is a clinical procedure and under pressure it is guaranteed that any vaccine candidate entering the trials will emerge successfully.
With regard to imaginable fitness headaches in recovering patients, Paul stated that subacute post-COVID morbidities such as respiratory symptoms, immune reactions in children, pulmonary fibrosis, etc., are an emerging and emerging “new dimension.” that communities are following her.
“We will have to be aware that this can have an effect in the future as well.We will use the remedy arrangements we have with us as needed to deal with those cases.This happens to some extent, but not at a dangerously alarming level,” Paul says.
On the reasons why on-demand testing is not being implemented for those willing to pay for it, Paul said the government would review the rules for testing.
When asked if the government was contemplating the use of tocilizumab as an experimental cure in the remedy of PATIENTS with COVID-19, Paul stated that for all medicines and interventions that are components of the national protocol of clinical remedy of COVID-19, the resolution that would come with them was based on the clinical evidence that was had that day.
Some remedies were not included because the evidence of that day was not favorable, he said, adding that it is a dynamic process.
Bhushan also indicated that the export of combinations of non-public protective appliances is subject to quantitative restrictions, while the export of enthusiasts is not subject to any such restrictions.
Coronavirus Essential Unlock 4.0 in India; The Oxford vaccine arrives in phase 3 trials in the US.Usa, Trump says